NASDAQ:TRVN - Trevena Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.74 +0.02 (+1.16 %)
(As of 05/27/2018 01:42 AM ET)
Previous Close$1.74
Today's Range$1.72 - $1.76
52-Week Range$1.34 - $3.10
Volume407,804 shs
Average Volume995,401 shs
Market Capitalization$116.91 million
P/E Ratio-1.44
Dividend YieldN/A
Beta-0.54

About Trevena (NASDAQ:TRVN)

Trevena logoTrevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Receive TRVN News and Ratings via Email

Sign-up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TRVN
CUSIPN/A
Phone610-354-8840

Debt

Debt-to-Equity Ratio0.35
Current Ratio4.11
Quick Ratio4.11

Price-To-Earnings

Trailing P/E Ratio-1.44
Forward P/E Ratio-2.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.75 million
Price / Sales31.54
Cash FlowN/A
Price / CashN/A
Book Value$0.53 per share
Price / Book3.28

Profitability

EPS (Most Recent Fiscal Year)($1.21)
Net Income$-71,860,000.00
Net MarginsN/A
Return on Equity-138.85%
Return on Assets-75.78%

Miscellaneous

Employees51
Outstanding Shares67,970,000

Trevena (NASDAQ:TRVN) Frequently Asked Questions

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

How were Trevena's earnings last quarter?

Trevena Inc (NASDAQ:TRVN) posted its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. View Trevena's Earnings History.

When is Trevena's next earnings date?

Trevena is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Trevena.

What price target have analysts set for TRVN?

5 brokers have issued twelve-month target prices for Trevena's shares. Their predictions range from $2.50 to $10.00. On average, they anticipate Trevena's stock price to reach $6.30 in the next twelve months. View Analyst Ratings for Trevena.

Who are some of Trevena's key competitors?

Who are Trevena's key executives?

Trevena's management team includes the folowing people:
  • Dr. Maxine Gowen, CEO, Pres & Exec. Director (Age 60)
  • Mr. John M. Limongelli, Chief Admin. Officer, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
  • Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Dr. Jonathan Violin Ph.D., Sr. VP of Scientific Affairs & Investor Relations Officer (Age 43)
  • Mr. Roberto E. Cuca, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 50)

Has Trevena been receiving favorable news coverage?

Headlines about TRVN stock have trended somewhat positive on Sunday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Trevena earned a media sentiment score of 0.06 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.46 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Trevena's major shareholders?

Trevena's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (1.28%), Northern Trust Corp (0.85%), Millennium Management LLC (0.70%), Schwab Charles Investment Management Inc. (0.22%), GSA Capital Partners LLP (0.18%) and JPMorgan Chase & Co. (0.13%). Company insiders that own Trevena stock include Carrie L Bourdow, Maxine Gowen and Yacoub Habib. View Institutional Ownership Trends for Trevena.

Which institutional investors are selling Trevena stock?

TRVN stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and GSA Capital Partners LLP. View Insider Buying and Selling for Trevena.

Which institutional investors are buying Trevena stock?

TRVN stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Schwab Charles Investment Management Inc. and Northern Trust Corp. Company insiders that have bought Trevena stock in the last two years include Carrie L Bourdow, Maxine Gowen and Yacoub Habib. View Insider Buying and Selling for Trevena.

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $1.74.

How big of a company is Trevena?

Trevena has a market capitalization of $116.91 million and generates $3.75 million in revenue each year. The biopharmaceutical company earns $-71,860,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Trevena employs 51 workers across the globe.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 200, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]


MarketBeat Community Rating for Trevena (TRVN)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  399 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  532
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Trevena (NASDAQ:TRVN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Trevena in the last 12 months. Their average twelve-month price target is $6.30, suggesting that the stock has a possible upside of 262.07%. The high price target for TRVN is $10.00 and the low price target for TRVN is $2.50. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.832.882.91
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.30$6.75$7.5625$9.3182
Price Target Upside: 262.07% upside279.21% upside324.86% upside423.49% upside

Trevena (NASDAQ:TRVN) Consensus Price Target History

Price Target History for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ:TRVN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2018CowenReiterated RatingBuy$10.00HighView Rating Details
5/3/2018OppenheimerSet Price TargetBuy$5.00HighView Rating Details
3/8/2018HC WainwrightBoost Price TargetBuy$7.00HighView Rating Details
11/8/2017Needham & Company LLCLower Price TargetBuy$9.00 ➝ $7.00N/AView Rating Details
10/16/2017BarclaysDowngradeOverweight ➝ Equal Weight$15.00 ➝ $2.50N/AView Rating Details
5/6/2017Roth CapitalSet Price TargetBuy$9.00MediumView Rating Details
4/17/2017AegisReiterated RatingBuy$14.00LowView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$8.00HighView Rating Details
2/16/2017Jefferies GroupReiterated RatingBuy$11.00N/AView Rating Details
2/2/2017Ladenburg ThalmannInitiated CoverageBuy$15.00N/AView Rating Details
12/1/2016WedbushReiterated RatingOutperform$16.00N/AView Rating Details
10/25/2016Brean CapitalSet Price TargetBuy$14.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Trevena (NASDAQ:TRVN) Earnings History and Estimates Chart

Earnings by Quarter for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ:TRVN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.21)($0.16)($0.18)
Q2 20183($0.20)($0.16)($0.18)
Q3 20183($0.22)($0.16)($0.20)
Q4 20183($0.23)($0.16)($0.21)

Trevena (NASDAQ TRVN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018($0.13)N/AView Earnings Details
5/3/2018Q1 2018($0.19)($0.14)ViewN/AView Earnings Details
3/7/2018Q4 2017($0.26)($0.24)ViewListenView Earnings Details
11/7/2017Q3 2017($0.33)($0.27)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.35)($0.35)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.55)($0.36)ViewN/AView Earnings Details
3/8/2017Q4 2016($0.62)($0.67)$0.48 millionViewListenView Earnings Details
11/3/2016Q3 2016($0.40)($0.57)$1.90 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.35)($0.37)$1.89 million$1.88 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.35)$1.93 million$1.88 millionViewN/AView Earnings Details
3/9/2016Q415($0.26)($0.30)$1.64 million$1.88 millionViewListenView Earnings Details
11/10/2015Q3($0.34)($0.24)$1.80 million$1.88 millionViewN/AView Earnings Details
8/11/2015Q215($0.3680)($0.28)$1.30 million$1.88 millionViewN/AView Earnings Details
5/7/2015($0.33)($0.33)$10.00 million$0.63 millionViewN/AView Earnings Details
3/18/2015Q414($0.39)($0.45)ViewN/AView Earnings Details
11/11/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/12/2014($0.35)($0.44)ViewN/AView Earnings Details
5/9/2014Q114($0.36)($0.59)$0.03 million$0.0412 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Trevena (NASDAQ:TRVN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Trevena (NASDAQ TRVN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 49.26%
Insider Trading History for Trevena (NASDAQ:TRVN)
Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ TRVN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2018Yacoub HabibSVPSell5,000$1.76$8,800.00View SEC Filing  
11/9/2016Carrie L BourdowSVPBuy4,000$4.34$17,360.00View SEC Filing  
11/7/2016Maxine GowenCEOBuy12,500$4.10$51,250.0016,500View SEC Filing  
11/7/2016Yacoub HabibSVPBuy5,000$4.12$20,600.005,000View SEC Filing  
5/27/2016Maxine GowenCEOBuy22,084$7.12$157,238.08279,025View SEC Filing  
12/10/2015David SoergelCMOSell27,217$10.55$287,139.351,750View SEC Filing  
12/12/2014John M LimongelliVPBuy3,000$4.14$12,420.00View SEC Filing  
12/10/2014Enterprise Associates 12 NewMajor ShareholderBuy1,000,000$4.00$4,000,000.00View SEC Filing  
12/10/2014Maxine GowenCEOBuy8,000$4.00$32,000.00View SEC Filing  
12/10/2014Michael R DoughertyDirectorBuy7,000$4.00$28,000.00View SEC Filing  
12/10/2014Michael W LarkVPBuy5,000$4.00$20,000.00View SEC Filing  
12/10/2014Roberto CucaCFOBuy25,000$4.00$100,000.00View SEC Filing  
12/9/2014Leon O Moulder JrDirectorBuy30,200$3.96$119,592.00View SEC Filing  
9/29/2014Rosamond DeeganSVPSell44$7.00$308.00View SEC Filing  
2/5/2014Laboratories Holdings L ForestMajor ShareholderBuy428,571$7.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Trevena (NASDAQ TRVN) News Headlines

Source:
DateHeadline
Blog Exposure - Trevena Showcases Data from ATHENA Phase-3 Study at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific MeetingBlog Exposure - Trevena Showcases Data from ATHENA Phase-3 Study at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting
finance.yahoo.com - May 24 at 8:21 AM
Trevena Inc (TRVN) Given Average Recommendation of "Buy" by AnalystsTrevena Inc (TRVN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 24 at 3:28 AM
BRIEF-Trevena Appoints Mark Demitrack As Chief Medical OfficerBRIEF-Trevena Appoints Mark Demitrack As Chief Medical Officer
www.reuters.com - May 22 at 8:19 AM
Trevena (TRVN) Names Mark A. Demitrack, MD, as Chief Medical OfficerTrevena (TRVN) Names Mark A. Demitrack, MD, as Chief Medical Officer
www.streetinsider.com - May 22 at 8:19 AM
Trevena Appoints Mark A. Demitrack, MD, as Chief Medical OfficerTrevena Appoints Mark A. Demitrack, MD, as Chief Medical Officer
globenewswire.com - May 22 at 8:19 AM
Trevena (TRVN) Lifted to "Buy" at Zacks Investment ResearchTrevena (TRVN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:59 PM
Trevenas (TRVN) Buy Rating Reiterated at CowenTrevena's (TRVN) Buy Rating Reiterated at Cowen
www.americanbankingnews.com - May 7 at 4:26 PM
FY2022 EPS Estimates for Trevena Inc Reduced by Jefferies Group (TRVN)FY2022 EPS Estimates for Trevena Inc Reduced by Jefferies Group (TRVN)
www.americanbankingnews.com - May 7 at 5:20 AM
Trevena (TRVN) PT Set at $5.00 by OppenheimerTrevena (TRVN) PT Set at $5.00 by Oppenheimer
www.americanbankingnews.com - May 4 at 10:31 PM
Trevena signs second international product licensing deal, this time for ChinaTrevena signs second international product licensing deal, this time for China
finance.yahoo.com - May 4 at 5:32 PM
Trevena (TRVN) Announces Quarterly  Earnings ResultsTrevena (TRVN) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 4 at 3:32 PM
Edited Transcript of TRVN earnings conference call or presentation 3-May-18 12:00pm GMTEdited Transcript of TRVN earnings conference call or presentation 3-May-18 12:00pm GMT
finance.yahoo.com - May 4 at 8:19 AM
BRIEF-Trevena Q1 Loss Per Share $0.14BRIEF-Trevena Q1 Loss Per Share $0.14
www.reuters.com - May 3 at 5:24 PM
Trevenas (TRVN) CEO Maxine Gowen on Q1 2018 Results - Earnings Call TranscriptTrevena's (TRVN) CEO Maxine Gowen on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 5:24 PM
Trevena: 1Q Earnings SnapshotTrevena: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 5:23 PM
-$0.19 Earnings Per Share Expected for Trevena Inc (TRVN) This Quarter-$0.19 Earnings Per Share Expected for Trevena Inc (TRVN) This Quarter
www.americanbankingnews.com - May 3 at 2:57 PM
Trevena Reports First Quarter 2018 Financial ResultsTrevena Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 8:17 AM
US STOCKS ON THE MOVE-Apple, HC2 Holdings, Juniper, Snap, Diebold, TrevenaUS STOCKS ON THE MOVE-Apple, HC2 Holdings, Juniper, Snap, Diebold, Trevena
www.nasdaq.com - May 2 at 5:35 PM
Trevena to Present at the Deutsche Bank 43rd Annual Healthcare ConferenceTrevena to Present at the Deutsche Bank 43rd Annual Healthcare Conference
finance.yahoo.com - May 2 at 5:35 PM
Trevena (TRVN) Upgraded by ValuEngine to SellTrevena (TRVN) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - May 2 at 3:48 PM
Trevena up 11% premarket on oliceridine deal in ChinaTrevena up 11% premarket on oliceridine deal in China
seekingalpha.com - May 2 at 8:22 AM
BRIEF-Trevena Inc And Jiangsu Nhwa Pharmaceutical Announce License Agreement For Oliceridine In ChinaBRIEF-Trevena Inc And Jiangsu Nhwa Pharmaceutical Announce License Agreement For Oliceridine In China
www.reuters.com - May 1 at 5:17 PM
Trevena Inc. and Jiangsu Nhwa Pharmaceutical Co. Ltd Announce License Agreement for Oliceridine in ChinaTrevena Inc. and Jiangsu Nhwa Pharmaceutical Co. Ltd Announce License Agreement for Oliceridine in China
finance.yahoo.com - May 1 at 5:17 PM
Trevena Inc (TRVN) Given Average Rating of "Buy" by AnalystsTrevena Inc (TRVN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 29 at 3:24 AM
$3M deal: Trevena signs licensing agreement with South Korean biopharm firm$3M deal: Trevena signs licensing agreement with South Korean biopharm firm
finance.yahoo.com - April 27 at 5:14 PM
Trevena to Report First Quarter 2018 Financial Results on May 3, 2018Trevena to Report First Quarter 2018 Financial Results on May 3, 2018
finance.yahoo.com - April 26 at 5:16 PM
Biotech Stocks Research Reports Released on TG Therapeutics, Trevena, Vanda Pharma, and VerastemBiotech Stocks' Research Reports Released on TG Therapeutics, Trevena, Vanda Pharma, and Verastem
www.prnewswire.com - April 25 at 8:21 AM
Trevena (TRVN) Set to Announce Earnings on WednesdayTrevena (TRVN) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 25 at 6:32 AM
Police use dead mans finger in failed bid to unlock his cellphonePolice use dead man's finger in failed bid to unlock his cellphone
www.nbcnews.com - April 24 at 8:20 AM
Zacks: Analysts Expect Trevena Inc (TRVN) to Post -$0.19 EPSZacks: Analysts Expect Trevena Inc (TRVN) to Post -$0.19 EPS
www.americanbankingnews.com - April 16 at 5:15 AM
Trevena (TRVN) PT Set at $8.00 by OppenheimerTrevena (TRVN) PT Set at $8.00 by Oppenheimer
www.americanbankingnews.com - April 13 at 10:53 AM
BRIEF-Trevena Says Chief Financial Officer Roberto Cuca Will Resign, Effective May 3, 2018BRIEF-Trevena Says Chief Financial Officer Roberto Cuca Will Resign, Effective May 3, 2018
www.reuters.com - April 13 at 8:20 AM
Form 8-K TREVENA INC For: Apr 09Form 8-K TREVENA INC For: Apr 09
www.streetinsider.com - April 12 at 5:38 PM
Barclays Lowers Trevena (TRVN) to Equal WeightBarclays Lowers Trevena (TRVN) to Equal Weight
www.americanbankingnews.com - April 7 at 10:53 AM
Zacks Investment Research Upgrades Trevena (TRVN) to "Buy"Zacks Investment Research Upgrades Trevena (TRVN) to "Buy"
www.americanbankingnews.com - April 6 at 3:01 PM
BRIEF-Trevena Announces Retirement Of Maxine Gowen, Ph.D., Effective October 1, And Planned Promotion Of Carrie ...BRIEF-Trevena Announces Retirement Of Maxine Gowen, Ph.D., Effective October 1, And Planned Promotion Of Carrie ...
www.reuters.com - April 5 at 5:17 PM
Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L ...Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L ...
globenewswire.com - April 5 at 5:17 PM
Trevena (TRVN) CEO Maxine Gowen to Retire; Announces Planned Promotion of Carrie L. Bourdow to President and ...Trevena (TRVN) CEO Maxine Gowen to Retire; Announces Planned Promotion of Carrie L. Bourdow to President and ...
www.streetinsider.com - April 5 at 5:17 PM
Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L. Bourdow to President and Chief Executive OfficerTrevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L. Bourdow to President and Chief Executive Officer
finance.yahoo.com - April 5 at 5:17 PM
Founding CEO of Trevena biopharm firm to retireFounding CEO of Trevena biopharm firm to retire
finance.yahoo.com - April 5 at 5:17 PM
Trevena Inc (TRVN) Given Average Rating of "Buy" by BrokeragesTrevena Inc (TRVN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 3:25 AM
Zacks Investment Research Lowers Trevena (TRVN) to HoldZacks Investment Research Lowers Trevena (TRVN) to Hold
www.americanbankingnews.com - April 2 at 8:21 AM
Needham & Company LLC Trims Trevena (TRVN) Target Price to $7.00Needham & Company LLC Trims Trevena (TRVN) Target Price to $7.00
www.americanbankingnews.com - April 1 at 10:29 AM
Edited Transcript of TRVN earnings conference call or presentation 7-Mar-18 1:00pm GMTEdited Transcript of TRVN earnings conference call or presentation 7-Mar-18 1:00pm GMT
finance.yahoo.com - April 1 at 8:23 AM
Trevenas (TRVN) "Buy" Rating Reiterated at OppenheimerTrevena's (TRVN) "Buy" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - March 22 at 4:05 PM
Trevena to Present at the Needham & Company 17th Annual Healthcare ConferenceTrevena to Present at the Needham & Company 17th Annual Healthcare Conference
finance.yahoo.com - March 20 at 5:16 PM
Trevena (TRVN) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowTrevena (TRVN) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 6:11 PM
Oppenheimer Analysts Lift Earnings Estimates for Trevena Inc (TRVN)Oppenheimer Analysts Lift Earnings Estimates for Trevena Inc (TRVN)
www.americanbankingnews.com - March 15 at 8:45 AM
Trevena to Present at the Oppenheimer & Company 28th Annual Healthcare ConferenceTrevena to Present at the Oppenheimer & Company 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 7:06 PM
Oppenheimer Weighs in on Trevena Incs FY2022 Earnings (TRVN)Oppenheimer Weighs in on Trevena Inc's FY2022 Earnings (TRVN)
www.americanbankingnews.com - March 14 at 4:24 PM

SEC Filings

Trevena (NASDAQ:TRVN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Trevena (NASDAQ:TRVN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Trevena (NASDAQ TRVN) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.